What the fresh guidance means for Ingredion stock Ingredion (INGR) has put updated numbers on the table. The company reaffirmed its full year 2026 earnings guidance and set expectations for modest net sales growth in the third quarter. This fresh guidance arrives alongside second quarter 2026 results, a completed buyback tranche, and progress on the proposed Tate & Lyle acquisition. Together, these developments give investors several new data points to weigh. See our latest analysis for...

Ingredion (NYSE:INGR) reported second-quarter 2026 results that were in line with its expectations, as continued growth in Texture & Healthful Solutions offset operational and macroeconomic pressures in other parts of the portfolio. Second-quarter net sales increased 1% year over year to $1.85

Ingredion's proposed $5 billion Tate & Lyle deal could expand its specialty platform and global reach, but approvals and integration risks remain.

In the late 1930s, Tate & Lyle chose to float on the London Stock Exchange (LSE) to reap the benefits of Britain’s recovering economy.

Tate & Lyle’s updated fair value estimate has shifted from £4.84 to £5.35, placing current analyst work more clearly in the mid £5 range that readers have seen referenced around recent price targets. That adjustment sits alongside commentary highlighting how the Ingredion offer and closely grouped targets between £5.47 and £5.95 are reshaping the risk and reward story, with several analysts moving to more neutral ratings. Keep reading to see how these numbers fit together and how to track the...

Zurich-based ABB said it would pay 506p a share for the engineering firm, which is headquartered in Bath.